Refine by
Pediatric Advanced Articles & Analysis
17 news found
PhotoniCare is honored to share that the TOMi Scope [OtoSight Middle Ear Scope] has been featured in the American Academy of Pediatrics (AAP) Section on Advances in Therapeutics and Technology (SOATT) Spring Newsletter. ...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and nView medical, a Salt Lake City-based company developing surgical imaging and guidance systems enabled by artificial intelligence (AI), today announced a partnership and investment agreement to jointly develop and co-market the innovative nView systems with Orthofix cervical spine and ...
With this 510(k) we also cleared AI-enabled image analysis and advanced imaging modes such as 3D stitching. This further increases the value we bring to customers.” The nView s1 with true-map navigation™ was first unveiled at the Pediatric Orthopedic Society of North America (POSNA) 2021 annual meeting. ...
During the conference, five startups from the Accelerator cohort will compete for the Execution Award, and another five companies will advance to compete in the Grand Final competition. An audience vote will determine the winner of the $350,000 grand prize and the title of 2021 MedTech Innovator. ...
During the conference, five startups from the Accelerator cohort will compete for the Execution Award, and another five companies will advance to compete in the Grand Final competition. An audience vote will determine the winner of the $350,000 grand prize and the title of 2021 MedTech Innovator. ...
During the conference, five startups from the Accelerator cohort will compete for the Execution Award, and another five companies will advance to compete in the Grand Final competition. An audience vote will determine the winner of the $350,000 grand prize and the title of 2021 MedTech Innovator. ...
The nView s1, nView medical’s breakthrough imaging system reached its 50th surgery. Twelve surgeons across three leading pediatric hospitals have used nView’s insta-3D™ technology on procedures ranging from spinal deformity corrections, to discectomies, periacetabular osteotomies and extremity procedures. nView medical CEO, Cristian Atria, commented: “To celebrate ...
NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat neurological and neuropsychiatric disorders, announced today that the following patents have issued or received notices of allowance in Canada and Japan: Canadian patent no. 2776694 entitled Devices, Systems, and Methods for Treatment of Neuropsychiatric ...
Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. Food and Drug Administration (FDA) in conjunction with five U.S. pediatric device consortia on 11 March. “I am looking forward to discussing the potential and the challenges of applying biomaterials to pediatric heart valve ...
“Children deserve to benefit from our most advanced medical technologies and we know that improvements in pediatric care can make a positive difference over the lifetime of a child,” says Kolaleh Eskandanian, Ph.D., M.B.A, P.M.P, vice president and chief innovation officer at Children’s National and principal investigator of NCC-PDI. ...
nView medical, a medical imaging company with breakthrough image creation technology, is preparing to pilot its first surgical scanner: the nView s1. This week HealthTech Arkansas announced that nView was selected out of a pool of hundreds of applicants to participate in its Accelerator Program, which guarantees pilots within its network of 11 healthcare providers: Arkansas Children’s ...
” competition presented by FDA-sponsored National Capital Consortium for Pediatric Device Innovation. The competition focused on innovations in COVID-19-related pediatric medical devices that will improve children’s health care, with 16 finalists competing in a virtual pitch event for a share of $250,000 in total grant awards. ...
Typical itch drugs take significantly longer to show improvement, highlighting a significant market opportunity for the company. The pediatric trial was an open-label, single dose level, multicenter, Phase 1b study of the B244 topical formulation, administered twice daily and was designed to assess its safety and tolerability in 28 pediatric patients aged 2 to ...
Typical itch drugs take significantly longer to show improvement, highlighting a significant market opportunity for the company. The pediatric trial was an open-label, single dose level, multicenter, Phase 1b study of the B244 topical formulation, administered twice daily and was designed to assess its safety and tolerability in 28 pediatric patients aged 2 to ...
Announced today, nView medical, a leading innovator in 3D medical imaging, and OrthoGrid Systems, Inc., a global MedTech leader offering intraoperative alignment technologies, are partnering to provide integrated solutions that increase surgical accuracy OR efficiency and improve patient outcomes As the first step for implementation, the companies are executing a proof of concept for a ...
“TOMi Scope’s [OtoSight Middle Ear Scope] advanced light-based technology could dramatically alter the way children with ear problems are evaluated, enhancing our ability to inform optimal ...
nView medical Inc. (nView) today announced the U.S. Food and Drug Administration (FDA) clearance of nView s1, the company’s first imaging system, bringing breakthrough imaging technology to surgery. nView’s mission is to make surgery safer, faster, and consistently accurate by creating instant 3D information throughout the surgical procedure. nView s1 integrates the latest ...